ICCC ImmuCell Corporation
USHealthcareAs of 2026-07-10 16:00
Why ICCC matters now
ImmuCell Corporation (ICCC) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.89 with -4.93% on the session and $98.5M in market capitalization; recent performance reads 1-month -6.96% and YTD +54.31%.
The latest financial table shown here is Q1 2026, with revenue of $10.4M, net income of $1.9M, and EPS of $0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 3.9%.
The latest indexable market news headline is "ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Guillemette Gilles filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.95
P/S
2.87
EV/EBITDA
38.48
DCF Value
$-13.39
FCF Yield
3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
42.6%
Operating Margin
8.4%
Net Margin
-1.8%
ROE
-1.9%
ROA
-1.2%
ROIC
6.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.4M | $1.9M | $0.21 |
| Q4 2025 | $7.6M | $-2.8M | $-0.31 |
| FY 2025 | $27.6M | $-1.0M | $-0.12 |
| Q3 2025 | $5.5M | $-139.7K | $-0.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.56
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.